Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 33« First...23456...102030...Last »

Healthcare Agency Roundtable 2016

Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.

Read More »

Novo, Sanofi face off with new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Read More »

NICE U-Turns, Backs Approval of Roche’s Perjeta

The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.

Read More »

No early win for cholesterol drug Praluent

Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.

Read More »

How Pharma Can Continue Moving Beyond the Pill

It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.

Read More »

U.S. watchdog told Medicare, Medicaid that EpiPen was misclassified in 2009: senator

The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.

Read More »

EpiPen rival plans on U.S. market return in 2017

Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.

Read More »

UK to ‘fast track’ most cost-effective new drugs

Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.

Read More »

Most U.S. dermatologists receive industry money

Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.

Read More »

Merrimack CEO Resigns, Company Slashes Jobs

Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.

Read More »

Regeneron’s Eylea combo therapy fails study

Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.

Read More »

Amgen’s Kyprolis falls short in study

Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Read More »

FDA approves J&J’s Stelara for Crohn’s disease

Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.

Read More »

Novartis’ Zykadia gets positive results

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

Read More »

U.S. approves Aralez pill for heart patients

The U.S. FDA approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.

Read More »

Takeda: Bold, New Access To Medicines Strategy

Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.

Read More »

Lung cancer doctors eye Keytruda over Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Read More »

Mylan offers discounts on EpiPen after criticism

Mylan NV said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program after lawmakers criticized the drug’s high price.

Read More »

Can anything contain U.S. drug costs?

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.

Read More »

2016 Annual Report: Top 200 Medicines

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

Read More »

Page 4 of 33« First...23456...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2017 Focus: Ad Agency Roundtable and more!

Subscribe

Ad Right Bottom

Main Navigation